Cord Blood America, Inc.(CBAI), through its wholly owned subsidiary CorCell Companies, Inc., is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. http://www.cordblood-america.com/ Insurance Partners
Blue Cross Blue ShieldOur current healthcare partners listed below have negotiated a special program for our customers to save cord blood for their children, grandchildren, nieces, nephews, friends or other loved ones. To learn more about our insurance partners visit the CorCell® website at www.corcell.com.
Blue Cross of Idaho's https://www.bcidaho.com/Health_Wellness/discount%20services/CorCell.asp
Asuris Northwest Health
Blue Cross Blue Shield of Kansas
Blue Cross Blue Shield of Northeastern Pennsylvania
Highmark Blue Cross Blue Shield West Virginia
HMSA - Blue Cross Blue Shield of Hawaii
Horizon Blue Cross Blue shield of New Jersey
Independence Blue Cross
Keystone, Personal Choice (part of IBC, and BCBS of North Eastern PA)
LifeWise Assurance Company
LifeWise Health Plan of Oregon
LifeWise Health Plan of Washington
Premera Blue Cross
Permera Blue Cross Blue Shield of Alaska
Regence Blue Shield
Regence BlueCross Blue Shield of Oregon
Regence BlueCross Blue Shield of Utah
Regence BlueCross Blue
__________________________________________________________________________________________________________________________________________________ Tissue Bank Director
Dr. O'Neill has 25 years experience in the industry, processed more than 50,000 specimens and has published 78 papers. Educated at the University of Glasgow in Scotland, Dr. O'Neill came to the United States in 1979 to work for the Memorial Sloan-Kettering Cancer Center in New York. While continuing to work in the field his experience continued to grow as he also was a Professor at various prestigious universities including:
Cornell University school of Medicine, NY;
Columbia University, NY;
Visiting Professor at the Institute of Immunology in Munich
Dr. Geoffrey O'Neill
https://www.sec.gov/cgi-bin/browse-edgar?company=cord+blood+america&owner=exclude&action=getcompany 2017 2nd Qtr Highlights
Cord Blood America Reports 2017 Second Quarter Results
August 11, 2017 - Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced financial results for the second quarter ended June 30, 2017.
Second Quarter Highlights Include:
Total revenue for the second quarter was $0.75 million, a decrease of 5.9% from total revenue of $0.79 million for the second quarter 2016.
Recurring storage revenue for the second quarter 2017 was $0.66 million, a decrease of 4.4% from recurring storage revenue of $0.69 million for the second quarter 2016.
EBITDA for the second quarter 2017 was $0.20 million, an increase of 151.9% from EBITDA of $0.08 million for the second quarter 2016.
Results of Operations for the Three-Months Ended June 30, 2017
For the three months ended June 30, 2017, total revenue was $0.75 million, a decrease of $0.04 million or 5.9% from $0.79 million in second quarter 2016. Of the $0.04 million decrease, approximately $0.03 million was attributable to the reduction in storage and processing revenue from a previously terminated agreement with a third party. The discontinuation of storage revenue from the third party accounted for the decline in the Company’s recurring storage revenue in the quarter.
Gross Profit for the three months ended June 30, 2017 was $0.57 million, a decrease of $0.02 million or 3.6% from $0.59 million in second quarter 2016. Of the $0.02 million decrease, approximately $0.03 million was attributable to the reduction in storage and processing revenue from the third party, offset by reductions made by the Company in cost of goods sold.
Gross Margin for the three months ended June 30, 2017 was 76.4% compared to 74.6% in second quarter 2016. Gross margin increased due to reductions made by the Company in cost of goods sold.
Net Income for the three months ended June 30, 2017 was $0.15 million compared to a loss of $0.03 million in second quarter 2016.
EBITDA for the three months ended June 30, 2017 was $0.20 million, an increase of $0.12 million or 151.9% from $0.08 in second quarter 2016 despite the reduction in revenue as the Company has reduced costs.
David Sandberg, Chairman of the Board, commented, “On July 7th, the Company made its final payment to Tonaquint which constituted payment in full of the original $2.5 million principal obligation and associated interest. The business is performing in line with our previous guidance and has net cash of approximately $0.73 mm while continuing to generate consistent cash flow. The board continues to evaluate ways to optimize shareholder value.” Current Share Structure
AS - 2,890,000,000
OS - 1,272,066,146